Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO Jeffrey Duchemin acquired 22,000 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was purchased at an average cost of $2.76 per share, for a total transaction of $60,720.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Insider Buying and Selling by Quarter for Harvard Bioscience (NASDAQ:HBIO)

WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/06/13/insider-buying-harvard-bioscience-inc-hbio-ceo-acquires-22000-shares-of-stock.html.

A number of large investors have recently made changes to their positions in the stock. Heartland Advisors Inc. boosted its stake in shares of Harvard Bioscience by 5.0% in the first quarter. Heartland Advisors Inc. now owns 2,100,000 shares of the medical instruments supplier’s stock worth $5,460,000 after buying an additional 100,000 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Harvard Bioscience by 1.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,631,348 shares of the medical instruments supplier’s stock worth $4,242,000 after buying an additional 20,499 shares in the last quarter. Royce & Associates LP raised its position in shares of Harvard Bioscience by 2.9% in the first quarter. Royce & Associates LP now owns 1,557,600 shares of the medical instruments supplier’s stock worth $4,050,000 after buying an additional 44,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Harvard Bioscience by 1.5% in the first quarter. Vanguard Group Inc. now owns 1,514,439 shares of the medical instruments supplier’s stock worth $3,937,000 after buying an additional 22,440 shares in the last quarter. Finally, Glacier Peak Capital LLC raised its position in shares of Harvard Bioscience by 77.0% in the fourth quarter. Glacier Peak Capital LLC now owns 1,156,332 shares of the medical instruments supplier’s stock worth $3,527,000 after buying an additional 503,208 shares in the last quarter. Hedge funds and other institutional investors own 61.98% of the company’s stock.

Several analysts have commented on the company. ValuEngine lowered Harvard Bioscience from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Zacks Investment Research raised Harvard Bioscience from a “sell” rating to a “hold” rating in a report on Friday, April 28th.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.